Study Id25736 Sanofi Statista Dossier

Sanofi
Sanofi
Table of Contents
Global positioning
06 Top 10 biotech and pharmaceutical companies based on market cap 2017
07 Top 50 pharmaceutical companies - Rx sales and R&D spending 2016
08 Total global prescription drug revenue from top 10 companies 2022
09 Leading global vaccine products by market share 2016 and 2022
Overview
11 Revenue of Sanofi 2006-2017
12 Sanofi top pharmaceutical products 2014-2017
13 Sanofi's net income 2007-2017
14 Sanofi's expenditure on research and development 2008-2017
15 Sanofi's total assets 2007-2017
16 Sanofi number of employees 2009-2017
Revenue distribution
18 Sanofi revenue by region 2017
19 Sanofi - revenue by segment 2014-2017
20 Sanofi - pharmaceutical segment revenues by product group 2015-2017
21 Sanofi: human vaccine revenues 2015-2017
22 Sanofi - revenue of animal health segment 2012-2016
Company shares
24 Average number of outstanding shares of Sanofi 2009-2017
25 Basic earnings per share of Sanofi 2009-2017
26 Cash dividend per share of Sanofi 2009-2017
Sanofi
Global positioning
Global positioning 6
Top 10 biotech and pharmaceutical companies based on market cap 2017

Top 10 biotech and pharmaceutical companies worldwide based on
market capitalization as of 2017 (in billion U.S. dollars)
data
0 50 100 150 200 250 300 350 400
Johnson & Johnson, U.S. 355.5
Novartis, Switzerland 225.3
Roche, Switzerland 218.2
Pfizer, U.S. 208.8
Merck, U.S. 178.5
AbbVie Inc, U.S. 141
Amgen, U.S. 138.4
Sanofi, France 123.4
Gilead Sciences, U.S. 109.3
Bristol-Myers Squibb, U.S. 102.5
Market cap in billion U.S. dollars
Note: Worldwide; as of September 2017
Further information regarding this statistic can be found on page 28.
Source: Thomson Reuters; Various sources; Financial Times ID 272716

Top 50 pharmaceutical companies - Rx sales and R&D spending 2016

Top 50 global pharmaceutical companies by prescription sales and R&D
spending in 2016 (in billion U.S. dollars)
Chart Title
Research and development spending Prescription sales
0 5 10 15 20 25 30 35 40 45 50
7.84
Pfizer (U.S.) 45.91
7.92
Novartis (Switzerland) 41.55
8.72
Roche (Switzerland) 39.55
9.76
Merck & Co. (U.S.) 35.56
5.72
Sanofi (France) 34.17
6.97
Johnson & Johnson (USA) 31.67
3.93
Gilead Sciences (U.S.) 29.99
4.7
GlaxoSmithKline (UK) 27.78
4.15
AbbVie (U.S.) 25.3
3.76
Amgen (U.S.) 21.89
5.63
AstraZeneca (UK) 20.97
2.85
Allergan (U.S.) 18.6
2.11
Teva Pharmaceutical Industries (Israel) 18.46
4.41
Bristol-Myers Squibb (U.S.) 18.16
Sales/spending in billion U.S. dollars
Note: Worldwide
Source: Pharmaceutical Executive; Evaluate ID 273029

Total global prescription drug revenue from top 10 companies 2022

Top 10 pharmaceutical companies based on global prescription drug
revenue in 2022 (in billion U.S. dollars)*
data
0 5 10 15 20 25 30 35 40 45 50 55
Novartis 49.8
Pfizer 49.7
Roche 49.6
Sanofi 41.7
Johnson & Johnson 40.5
Merck & Co 38.5
AbbVie 34
GlaxoSmithKline 33.7
AstraZeneca 28.4
Celgene 26
Prescription drug revenue in billion U.S. dollars
Note: Worldwide; as of May 2017
Source: Evaluate ID 309422

Leading global vaccine products by market share 2016 and 2022

Top 5 global vaccine products by market share in 2016 and 2022
Chart Title
2022 2016
0.0% 5.0% 10.0% 15.0% 20.0% 25.0%
16.3%
Prevnar 13 (Pfizer + Daewoong)
21.9%
7.1%
Gardasil (Merck & Co)
9%
6%
Pentacel (Sanofi)
6%
5.9%
Fluzone (Sanofi)
6.1%
3.3%
Bexsero (GlaxoSmithKline)
1.9%
Market share
Note: Worldwide; as of May 2017
Source: Evaluate ID 314572

Sanofi
Overview
Overview 11
Revenue of Sanofi 2006-2017

Revenue of Sanofi from 2006 to 2017 (in million euros)
data
40000
34,743 35,055
35000 34,060 33,821
33,389
32,367
31,380
30,693
29,785
30000 28,373 28,052 27,568
25000
Revenue in million euros
20000
15000
10000
5000
0
2006 2007 2008 2009 2010 2011* 2012* 2013 2014 2015 2016** 2017
Note: Worldwide
Source: Sanofi ID 266509

Overview 12
Sanofi top pharmaceutical products 2014-2017

Sanofi's selected top pharmaceutical products based on revenue from
2014 to 2017 (in million euros)
Chart Title
2017 2016 2015 2014
0 1000 2000 3000 4000 5000 6000 7000

4,622
5,714
Lantus 6,390
6,344
1,575
1,636
Lovenox 1,719
1,699
1,567
1,295
Aubagio 871
433
1,471
1,544
Plavix 1,929
1,862
816
649
Toujeo
802
922
Renagel/Renvela 935
684
789
725
Myozyme/Lumizyme 650
542
691
681
Aprovel 762
727
Note: Worldwide

Overview 13
Sanofi's net income 2007-2017

Sanofi's net income from 2007 to 2017 (in million euros)*
data
9000
8,434
8000
7000
6000 5,646
5,467
Net income in million euros
5,263 5,265
4,888
5000 4,709
4,390 4,287
3,851
4000 3,716
3000
2000
1000
0
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Note: Worldwide

Overview 14
Sanofi's expenditure on research and development 2008-2017

Sanofi's expenditure on research and development from 2008 to 2017 (in
million euros)
data
6000
5,472
5,172
5,082
4,922
5000 4,811
4,628 4,605 4,667
4,575 4,556
4000
Expenditure in million euros
3000
2000
1000
0
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Note: Worldwide

Overview 15
Sanofi's total assets 2007-2017

Sanofi's total assets from 2007 to 2017 (in million euros)
data
120000
104,672
102,321
100,672 100,399 99,826
100000 96,055 97,392
85,264
80,251
80000
Total assets in million euros
71,914 71,987
60000
40000
20000
0
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Note: Worldwide

Overview 16
Sanofi number of employees 2009-2017

Sanofi's number of employees from 2009 to 2017
data
140000
120000 115,631
113,719 111,974 112,128 113,496
106,859 106,566
104,867
101,575
100000
Number of employees
80000
60000
40000
20000
0
2009 2010 2011 2012 2013 2014 2015 2016* 2017
Note: Worldwide

Sanofi
Revenue distribution
Revenue distribution 18
Sanofi revenue by region 2017

Revenue of Sanofi by region in 2017 (in million euros)
data
14000
11,855
12000
10,258
10000 9,525
8000
6000
3,732
4000 3,417
2,837
2,326
1,803
2000
1,242
426
0
United States Emerging of which Asia of which Latin of which Africa Eurasia** Europe*** Rest of the of which Japan of which South
markets* (excluding America & Middle East world **** Korea
South Asia)
Note: Worldwide

Sanofi - revenue by segment 2014-2017

Revenue of Sanofi by segment from 2014 to 2017 (in million euros)
Chart Title
2014 2015 2016 2017
35000
30000
25000
20000
15000
10000
5000
0
Pharmaceuticals Vaccines Consumer Healthcare* Animal Health*
Note: Worldwide

Sanofi - pharmaceutical segment revenues by product group 2015-2017

Revenue of Sanofi's pharmaceutical segment by product group from 2015
to 2017 (in million euros)
Chart Title
2017 2016 2015
0 2000 4000 6000 8000 10000 12000
9,761
Established prescription products 10,311
11,292
6,395
Diabetes 7,341
7,580
4,832
Consumer health care 3,330
3,492
2,888
Rare diseases 2,777
2,550
2,041
Multiple sclerosis 1,720
1,114
1,778
Generics 1,854
1,917
1,519
Oncology 1,453
1,504
510
Cardiovascular 458
350
230
Immunology
Note: Worldwide

Sanofi: human vaccine revenues 2015-2017

Sanofi's human vaccine revenues in 2015 and 2017, by area of application
(in million euros)
Chart Title
2017 2016 2015
0 200 400 600 800 1000 1200 1400 1600 1800 2000
1,827
Polio, pertussis, hib 1,495
1,348
1,589
Influenza vaccines 1,521
1,322
623
Meningitis, pneumonia 633
614
493
Travel and other endemics diseases 368
375
474
Adult booster vaccines 417
496
3
Dengvaxia 55
92
Other vaccines 88
106
Note: Worldwide

Sanofi - revenue of animal health segment 2012-2016

Revenue of Sanofi 's Animal Health segment from 2012 to 2016 (in million
euros)
Chart Title
Companion animals Production animals Total animal health
3000
2,708
2,515
2500
2,179
2,076
1,985
2000
1,781
1,629
1500 1,372
1,281
1,195
1000 927
886
807 790 795
500
0
2012 2013 2014 2015 2016
Note: Worldwide

Sanofi
Company shares
Company shares 24
Average number of outstanding shares of Sanofi 2009-2017

Number of Sanofi's outstanding shares from 2009 to 2017 (in million
shares)
data
1400
1,305.9 1,321.7 1,319.5 1,323.1 1,315.8 1,306.2
1,305.3
1,286.6
1,256.9
1200
1000
Average number of shares in millions
800
600
400
200
0
2009 2010 2011 2012 2013 2014 2015 2016 2017
Note: Worldwide

Company shares 25
Basic earnings per share of Sanofi 2009-2017

Basic earning's per Sanofi's shares from 2009 to 2017 (in euros)
data
7 6.71
6
Earnings per share in euros
4.31
4.19
4.03
4 3.71 3.66
3.34 3.28
3 2.81
0
2009 2010 2011 2012 2013 2014 2015 2016 2017
Note: Worldwide

Company shares 26
Cash dividend per share of Sanofi 2009-2017

Cash dividend per share of Sanofi from 2009 to 2017 (in euros)*
data
3.5
3.03
2.93 2.96
3 2.85
2.77 2.8
2.65
2.5
2.5 2.4
Cash dividend per share in euros
1.5
0.5
0
2009 2010 2011 2012 2013 2014 2015 2016 2017
Note: Worldwide

Sanofi
References
References 28
Top 10 biotech and pharmaceutical companies based on market cap 2017

Top 10 biotech and pharmaceutical companies worldwide based on
market capitalization as of 2017 (in billion U.S. dollars)
Source and methodology information Notes:

Release date represents date figures were accessed.
Source Thomson Reuters; Various sources; Financial Times
Conducted by Thomson Reuters; Various sources
Survey period as of September 2017
Region Worldwide
Number of respondents n.a.
Age group n.a.
Special characteristics n.a.
Published by Financial Times
Publication date September 2017
Original source markets.ft.com
Website URL visit the website

References 29
Top 50 pharmaceutical companies - Rx sales and R&D spending 2016

Top 50 global pharmaceutical companies by prescription sales and R&D
spending in 2016 (in billion U.S. dollars)

No value means no data available. "0" in fact means larger than 0 and
smaller than 0,01.
Source Pharmaceutical Executive; Evaluate
Conducted by Pharmaceutical Executive; Various sources (company

data); Evaluate (EvaluatePharma)
Survey period 2016
Region Worldwide
Age group n.a.
Published by Pharmaceutical Executive
Publication date June 2017
Original source pharmexec.com

References 30
Total global prescription drug revenue from top 10 companies 2022

Top 10 pharmaceutical companies based on global prescription drug
revenue in 2022 (in billion U.S. dollars)*

* All values are projections.
Source Evaluate
Conducted by Evaluate (EvaluatePharma)
Survey period as of May 2017
Region Worldwide
Age group n.a.
Published by Evaluate
Original source EvaluatePharma - World Preview 2017, Outlook to

2022, page 10

References 31
Leading global vaccine products by market share 2016 and 2022

Top 5 global vaccine products by market share in 2016 and 2022

Statistic is ranked by 2022 market share based on revenues. Figures for 2022
are forecasted.
Source Evaluate
Conducted by Evaluate (EvaluatePharma)
Survey period as of May 2017
Region Worldwide
Age group n.a.
Published by Evaluate
Original source EvaluatePharma - World Preview 2017, Outlook to

2022, page 32

References 32
Revenue of Sanofi 2006-2017

Revenue of Sanofi from 2006 to 2017 (in million euros)

Figures for 2006-2012 were quoted from previous annual reports. * Including
the Animal Health business, the net income/loss of which is presented in a
Source Sanofi separate line item,.For 2012 and 2011, it is not practicable to provide
information excluding the Animal Health business withoutunreasonable effort
or expense. ** Due to a change in accounting presentation, VaxServe sales
Conducted by Sanofi of non-Sanofi products are included in Other revenues from 2016 onwards.
The presentation of prior period Net sales and Other revenues has been
amended accordingly.
Survey period 2006 to 2017
Region Worldwide
Age group n.a.
Published by Sanofi
Publication date March 2018
Original source Sanofi - 2017 Form 20-F, page 2

References 33
Sanofi top pharmaceutical products 2014-2017

Sanofi's selected top pharmaceutical products based on revenue from
2014 to 2017 (in million euros)

This statistic was assembled from several financial reports.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi
Original source Sanofi - 2017 Form 20-F, page 91-92

References 34
Sanofi's net income 2007-2017

Sanofi's net income from 2007 to 2017 (in million euros)*

* Net income attributable to equity holders of Sanofi. Figures for 2007-2012
were quoted from previous annual financial reports.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 35
Sanofi's expenditure on research and development 2008-2017

Sanofi's expenditure on research and development from 2008 to 2017 (in
million euros)

Figures for 2008-2015 were taken from previous annual financial reports.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 36
Sanofi's total assets 2007-2017

Sanofi's total assets from 2007 to 2017 (in million euros)

Figures for 2007-2012 were quoted from previous annual financial reports.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 37
Sanofi number of employees 2009-2017

Sanofi's number of employees from 2009 to 2017

All figures as of year-end. This statistic was assembled from several financial
reports. * Excludes workforce for the Animal Health business of 6,957
Source Sanofi employees in 2016. During 2016, the Animal Health segment was the object
of a swap deal between Sanofi and Boehringer Ingelheim. Thus it is no longer
included in Sanofi's total figures.
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 38
Sanofi revenue by region 2017

Revenue of Sanofi by region in 2017 (in million euros)

* World excluding United States, Canada, Western and Eastern Europe
(apart from Eurasia), Japan, South Korea, Australia, New Zealand and Puerto
Source Sanofi Rico. ** Russia, Ukraine, Georgia, Belarus, Armenia and Turkey. *** Western
Europe and Eastern Europe (excluding Eurasia). **** Japan, South Korea,
Canada, Australia, New Zealand and Puerto Rico.
Conducted by Sanofi
Survey period 2017
Region Worldwide
Age group n.a.
Published by Sanofi

References 39
Sanofi - revenue by segment 2014-2017

Revenue of Sanofi by segment from 2014 to 2017 (in million euros)

* During 2016, the Animal Health and the Consumer Healthcare segments
were the objects of a swap deal between Sanofi and Boehringer Ingelheim.
Source Sanofi Since 2016, Animal Health revenues were no longer part of Sanofi's total
revenues.
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 40
Sanofi - pharmaceutical segment revenues by product group 2015-2017

Revenue of Sanofi's pharmaceutical segment by product group from 2015
to 2017 (in million euros)

n.a.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 41
Sanofi: human vaccine revenues 2015-2017

Sanofi's human vaccine revenues in 2015 and 2017, by area of application
(in million euros)

This statistic was assembled from several financial reports.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 42
Sanofi - revenue of animal health segment 2012-2016

Revenue of Sanofi 's Animal Health segment from 2012 to 2016 (in million
euros)

* In 2016, the Animal Health segment was the object of swap deal between
Sanofi and Boehringer Ingelheim. Thus, it is no longer part of Sanofi.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 43
Average number of outstanding shares of Sanofi 2009-2017

Number of Sanofi's outstanding shares from 2009 to 2017 (in million
shares)

Figures prior to 2016 were taken from previous editions.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 44
Basic earnings per share of Sanofi 2009-2017

Basic earning's per Sanofi's shares from 2009 to 2017 (in euros)

Figures prior to 2016 were taken from previous editions.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

References 45
Cash dividend per share of Sanofi 2009-2017

Cash dividend per share of Sanofi from 2009 to 2017 (in euros)*

* Each American Depositary Share, or ADS, represents one half of one share.
Source Sanofi
Conducted by Sanofi
Region Worldwide
Age group n.a.
Published by Sanofi

Study Id25736 Sanofi Statista Dossier

Transféré par

Informations du document

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

Study Id25736 Sanofi Statista Dossier

Transféré par

Droits d'auteur :

Formats disponibles

Sanofi

Top 10 biotech and pharmaceutical companies based on market cap 2017

0 50 100 150 200 250 300 350 400

Johnson & Johnson, U.S. 355.5

Novartis, Switzerland 225.3

Roche, Switzerland 218.2

Pfizer, U.S. 208.8

Merck, U.S. 178.5

AbbVie Inc, U.S. 141

Amgen, U.S. 138.4

Sanofi, France 123.4

Gilead Sciences, U.S. 109.3

Bristol-Myers Squibb, U.S. 102.5

Market cap in billion U.S. dollars

Note: Worldwide; as of September 2017

Further information regarding this statistic can be found on page 28.

Source: Thomson Reuters; Various sources; Financial Times ID 272716

Top 50 pharmaceutical companies - Rx sales and R&D spending 2016

Research and development spending Prescription sales

Further information regarding this statistic can be found on page 29.

Source: Pharmaceutical Executive; Evaluate ID 273029

Total global prescription drug revenue from top 10 companies 2022

Johnson & Johnson 40.5

Merck & Co 38.5

Prescription drug revenue in billion U.S. dollars

Note: Worldwide; as of May 2017

Further information regarding this statistic can be found on page 30.

Source: Evaluate ID 309422

Leading global vaccine products by market share 2016 and 2022

0.0% 5.0% 10.0% 15.0% 20.0% 25.0%

Note: Worldwide; as of May 2017

Further information regarding this statistic can be found on page 31.

Source: Evaluate ID 314572

Revenue of Sanofi 2006-2017

Further information regarding this statistic can be found on page 32.

Source: Sanofi ID 266509

Sanofi top pharmaceutical products 2014-2017

2017 2016 2015 2014

0 1000 2000 3000 4000 5000 6000 7000

Further information regarding this statistic can be found on page 33.

Source: Sanofi ID 266506

Sanofi's net income 2007-2017

Further information regarding this statistic can be found on page 34.

Source: Sanofi ID 279203

Sanofi's expenditure on research and development 2008-2017

Further information regarding this statistic can be found on page 35.

Source: Sanofi ID 279202

Sanofi's total assets 2007-2017

Further information regarding this statistic can be found on page 36.

Source: Sanofi ID 279204

Sanofi number of employees 2009-2017

Further information regarding this statistic can be found on page 37.

Source: Sanofi ID 382412

Sanofi revenue by region 2017

Further information regarding this statistic can be found on page 38.

Source: Sanofi ID 382016

Sanofi - revenue by segment 2014-2017

2014 2015 2016 2017

Further information regarding this statistic can be found on page 39.

Source: Sanofi ID 266504

Sanofi - pharmaceutical segment revenues by product group 2015-2017

2017 2016 2015

0 2000 4000 6000 8000 10000 12000

Revenue in million euros